Skip to content

Septerna, Inc. SEPN Free cash flow yield

Free cash flow yield at other companies

Amgen logo
AmgenAMGN
4.5%-2.0pp
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
19.2%+13.6pp
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-16.6%-0.6pp
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-5.4%-2.2pp
Maze Therapeutics, Inc. Common Stock logo
Maze Therapeutics, Inc. Common StockMAZE
-8.3%
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
22.9%+19.6pp

Other financials

Income statement

See full
Revenue$26.5M+12,011%
Operating income-$13.3M+48.7%
Net income-$8.6M+59.8%
EPS (diluted)-$0.19+61.2%

Balance sheet

See full
Cash & equivalents$71.6M-65.9%
Total debt$23.1M-7.7%
Total equity$378.5M+195%
Total assets$569.7M+31.3%

Cash flow

See full
Operating cash flow-$25.6M-9.8%
CapEx$832.0K+118%
Free cash flow-$26.5M-11.5%

Valuation

See full
Market cap$1.62B+319%
Enterprise value$1.58B+1,325%
P/S22.5×-374×

Profitability

See full
Operating margin-77.1%-38.4pp
Net margin-49.9%-24.9pp
FCF margin467.9%+243pp

Returns & leverage

See full
Return on equity-12.2%
Debt / equity0.1×
Current ratio4.7×-27.5×

Where this comes from

Calculated from Septerna, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Septerna, Inc.’s 10-Q, filed November 10, 2025, on SEC EDGAR. View the filing →

Ask your AI about Septerna, Inc.'s free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Septerna, Inc.'s free cash flow yield?
Septerna, Inc. (SEPN) reported free cash flow yield of 12.3% in Q3 2025.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.